1.Lewis-Jones H，Colley S，Gibson D，et al. Imaging in head and neck cancer：United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016；130（S2）：S28-S31.

2.Pan R，Zhu M，Yu C，et al. Cancer incidence and mortality：A cohort study in China，2008-2013. Int J Cancer. 2017；141（7）：1315-1323.

3.Argiris A，Karamouzis MV，Raben D，et al. Head and neck cancer. Lancet. 2008；371（9625）：1695-1709.

4.Gillison ML，Chaturvedi AK，Anderson WF，et al. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015；33（29）：3235-3242.

5.Goel R，Moore W，Sumer B，et al. Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. AJR Am J Roentgenol. 2017；209（2）：289-303.

6.Yongkui L1，Jian L，Wanghan，et al. 18FDG-PET/CT for the detection of regional nodal metastasis in patients with primary head and neck cancer before treatment：a meta-analysis. Surg Oncol. 2013；22（2）：e11-16.

7.Gao S，Li S，Yang X，et al. 18FDG PET/CT for distant metastases in patients with recurrent head and neck cancer after definitive treatment. A meta-analysis. Oral Oncol. 2014；50（3）：163-167.

8.Lonneux M，Hamoir M，Reychler H，et al. Positron emission tomography with [18F] fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma：a multicenter prospective study. J Clin Oncol. 2010；28（7）：1190-1195.

9.National Comprehensive Cancer Network. NCCN clinical practice guidelines：head and neck cancers，version 2，2017. Ft. Washington，PA：NCCN，2017.